Array BioPharma has reported that the Phase 2 trial of ARRY-797 in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs) met its primary endpoint.

The treatment with ARRY-797, a novel, oral, selective p38 inhibitor, resulted in a statistically significant reduction in pain over a 28-day period compared to placebo, as measured using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale (a 0-10 numerical pain rating scale).

The Altoona Arthritis and Osteoporosis Center founder and a study investigator Alan Kivitz said the study results with ARRY-797 showed promising benefit in the management of pain in osteoarthritis patients who are refractory to NSAIDS.

"This study was designed with a high hurdle in mind, which this drug was able to overcome," Kivitz added.

Patients receiving ARRY-797 in the study experienced a mean reduction in the WOMAC pain subscale score at day 28 vs. baseline that was 0.8 greater than those receiving placebo (2.4 vs. 1.6; one-sided p = 0.0247).

WOMAC physical function, WOMAC stiffness, responder analysis and the Patient’s Global Impression of Change, additional endpoints, also showed improvement relative to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ARRY-797 was considered to be well-tolerated at the selected dose of 400mg twice-daily, with the most common adverse events observed in patients being dizziness, diarrhoea and nausea.

ARRY-797 treatment was associated with sporadic, transient increases in creatine kinase and aspartate aminotransferase.

The mild prolongations of the QTc interval and sustained decreases in systolic and diastolic blood pressure were also observed in the trial.

Array BioPharma chief executive officer Ron Squarer said, "These results, together with our earlier studies in acute pain, provide evidence that ARRY-797 delivers therapeutic utility in both acute and chronic pain settings."